Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 trial of TRN-001

Next Previous
Trial Profile

A phase 1 trial of TRN-001

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 31 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TRN-001 (Primary)
  • Indications Skin disorders
  • Focus Adverse reactions
  • Sponsors Daewoong Pharmaceutical; HanAll Biopharma

Most Recent Events

  • 26 Mar 2025 According to a Turn Biotechnologies media release, company acquired the license to the ARMMs delivery technology from Harvard University, along with all associated assets from Vesigen Therapeutics of Cambridge, Massachusetts, to advance TRN-001 candidate, which uses the company's eTurna platform.
  • 18 Apr 2022 New trial record
  • 11 Apr 2022 According to a Daewoong Pharmaceutical and HanAll Biopharma media release, financing from these companies will support Turn Bio's advancement towards a phase 1 trial of its mRNA therapy candidate TRN-001

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top